Published in J Biol Chem on April 25, 1981
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci U S A (1990) 2.79
Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun (1992) 2.73
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
Plasma fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. J Exp Med (1983) 2.49
Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest (1988) 2.38
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A (1981) 2.02
Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci U S A (1982) 1.96
Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med (1988) 1.92
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun (1996) 1.79
Mechanisms of platelet aggregation by viridans group streptococci. Infect Immun (1987) 1.77
Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins. Infect Immun (1989) 1.76
Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest (1982) 1.75
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol (2009) 1.70
Connective tissue proteins and phagocytic cell function. Laminin enhances complement and Fc-mediated phagocytosis by cultured human macrophages. J Exp Med (1985) 1.62
Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest (1995) 1.57
Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med (1992) 1.56
Localization of complement component 3 on Streptococcus pneumoniae: anti-capsular antibody causes complement deposition on the pneumococcal capsule. Infect Immun (1983) 1.51
Analysis of C3-receptor activity on human B-lymphocytes and isolation of the complement receptor type 2 (CR2). Biochem J (1984) 1.51
Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med (1988) 1.51
Studies on the fibronectin receptors of human peripheral blood leukocytes. Morphologic and functional characterization. J Exp Med (1984) 1.48
Human mannose-binding protein activates the alternative complement pathway and enhances serum bactericidal activity on a mannose-rich isolate of Salmonella. J Clin Invest (1989) 1.47
In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J Exp Med (1999) 1.46
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H. Biochem J (1984) 1.44
Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem J (1994) 1.42
Interaction of human complement with Sbi, a staphylococcal immunoglobulin-binding protein: indications of a novel mechanism of complement evasion by Staphylococcus aureus. J Biol Chem (2008) 1.42
Mechanism of bacterial resistance to complement-mediated killing: inserted C5b-9 correlates with killing for Escherichia coli O111B4 varying in O-antigen capsule and O-polysaccharide coverage of lipid A core oligosaccharide. Infect Immun (1984) 1.42
Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J (1985) 1.38
Mechanism of action of blocking immunoglobulin G for Neisseria gonorrhoeae. J Clin Invest (1985) 1.35
Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest (1986) 1.35
Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci U S A (1983) 1.35
Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b to antibody molecules. Infect Immun (1983) 1.31
Activation of C3 and binding to Aspergillus fumigatus conidia and hyphae. Infect Immun (1989) 1.31
C3d receptors are expressed on human monocytes after in vitro cultivation. Proc Natl Acad Sci U S A (1983) 1.30
The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J (1986) 1.26
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest (1989) 1.25
Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death. J Exp Med (1982) 1.25
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc Natl Acad Sci U S A (1988) 1.22
Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces. J Clin Invest (1992) 1.22
Epstein-Barr virus regulates activation and processing of the third component of complement. J Exp Med (1988) 1.21
Third component of human complement: localization of the internal thiolester bond. Proc Natl Acad Sci U S A (1982) 1.20
Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1986) 1.20
Sequence determination of the thiolester site of the fourth component of human complement. Proc Natl Acad Sci U S A (1981) 1.19
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol (2010) 1.18
Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor. J Exp Med (1991) 1.18
gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes. J Exp Med (1985) 1.17
The opsonizing ligand on Salmonella typhimurium influences incorporation of specific, but not azurophil, granule constituents into neutrophil phagosomes. J Cell Biol (1989) 1.16
Loss of complement receptor type 1 (CR1) on ageing of erythrocytes. Studies of proteolytic release of the receptor. Biochem J (1986) 1.16
Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest (1987) 1.16
Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. J Clin Invest (1993) 1.15
Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci U S A (1985) 1.14
The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun (2002) 1.14
Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A (1986) 1.14
Lymphoblastoid cell supernatants increase expression of C3b receptors on human polymorphonuclear leucocytes: direct binding studies with 125I-C3b. Immunology (1984) 1.14
Isolation and biochemical characterization of the iC3b receptor of Candida albicans. Infect Immun (1993) 1.12
IgG bearing covalently bound C3b has enhanced bactericidal activity for Escherichia coli 0111. J Exp Med (1985) 1.11
Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem (2009) 1.09
Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology (2010) 1.05
The role of complement component C3b and its receptors in sperm-oocyte interaction. Proc Natl Acad Sci U S A (1993) 1.05
Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest (1985) 1.04
A natural model of immunologic tolerance. Tolerance to murine C5 is mediated by T cells, and antigen is required to maintain unresponsiveness. J Exp Med (1982) 1.04
The origin of the very variable haemolytic activities of the common human complement component C4 allotypes including C4-A6. EMBO J (1985) 1.03
Difference in the biological properties of the two forms of the fourth component of human complement (C4). Clin Exp Immunol (1986) 1.03
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans. Clin Exp Immunol (1987) 1.02
Aspergillus fumigatus complement inhibitor: production, characterization, and purification by hydrophobic interaction and thin-layer chromatography. Infect Immun (1990) 0.99
Isolation of two molecular populations of human complement factor H by hydrophobic affinity chromatography. Biochem J (1984) 0.99
The complement fragment C3d facilitates phagocytosis by monocytes. Immunology (1987) 0.99
Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J Immunol (2010) 0.98
Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect Immun (1998) 0.98
Identification of complement regulatory domains in vaccinia virus complement control protein. J Virol (2005) 0.98
Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest (1985) 0.98
Complement activation and C3 binding by serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa. Infect Immun (1989) 0.97
Enzymic assay of C3b receptor on intact cells and solubilized cells. Biochem J (1983) 0.97
Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides. Biochem J (1990) 0.96
Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol (2001) 0.95
Studies on phagocytosis in patients with acute bacterial infections. J Clin Invest (1989) 0.95
Serum amyloid P component bound to gram-negative bacteria prevents lipopolysaccharide-mediated classical pathway complement activation. Infect Immun (2000) 0.93
The role of C1, C1-inactivator and C4 in modulating immune precipitation. Clin Exp Immunol (1985) 0.90
Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. Immunology (1987) 0.88
Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification. Biochem J (2000) 0.88
Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule. Mol Microbiol (2009) 0.88
The Bb fragment of complement factor B acts as a B cell growth factor. J Exp Med (1988) 0.88
Antigenic relationship between the alpha-chain of C3, a leucocyte-surface antigen involved in the activation of phagocytic cells, and a 50,000 MW B-cell antigen. Immunology (1985) 0.88
Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans. Infect Immun (2006) 0.88
Purification and characterization of IgG immunoconglutinins from patients with systemic lupus erythematosus: implications for a regulatory function. Clin Exp Immunol (1990) 0.87
Decomplementation antigen, a possible determinant of staphylococcal pathogenicity. Infect Immun (1985) 0.87
Naturally occurring anti-band 3 antibodies have a unique affinity for C3. Immunology (1993) 0.87
Detection and characterization of immunoconglutinins in patients with systemic lupus erythematosus (SLE): serial analysis in relation to disease course. Clin Exp Immunol (1992) 0.87
Leishmanial protein kinases phosphorylate components of the complement system. EMBO J (1991) 0.87
Dynamic structural changes during complement C3 activation analyzed by hydrogen/deuterium exchange mass spectrometry. Mol Immunol (2008) 0.86
Contribution of chondroitin sulfate A to the binding of complement proteins to activated platelets. PLoS One (2010) 0.84
Functional analysis and quantification of the complement C3 derived anaphylatoxin C3a with a monoclonal antibody. Clin Exp Immunol (1987) 0.84
Role of CD47 as a marker of self on red blood cells. Science (2000) 7.00
Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci U S A (1998) 3.85
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
Tritium labeling of proteins to high specific radioactivity by reduction methylation. J Biol Chem (1980) 3.04
Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci U S A (1980) 3.00
CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptor-mediated phagocytosis. J Exp Med (2001) 2.75
Decreased resistance to bacterial infection and granulocyte defects in IAP-deficient mice. Science (1996) 2.55
Synergistic and additive killing by antimicrobial factors found in human airway surface liquid. Am J Physiol Lung Cell Mol Physiol (2000) 2.55
The cDNA sequence for the protein-tyrosine kinase substrate p36 (calpactin I heavy chain) reveals a multidomain protein with internal repeats. Cell (1986) 2.36
A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest (1982) 2.33
Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun (2000) 2.24
Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun (1999) 2.19
Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol (1993) 2.10
Discovery of new human beta-defensins using a genomics-based approach. Gene (2001) 2.08
Metabolism of gallic acid and syringic acid by Pseudomonas putida. J Biol Chem (1972) 2.04
Purification and properties of 4-hydroxy-4-methyl-2-oxoglutarate aldolase. J Biol Chem (1972) 2.04
Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci U S A (1981) 2.02
Studies of the molecular mechanisms of C3b inactivation and a simplified assay of beta 1H and the C3b inactivator (C3bINA). J Immunol (1979) 2.01
The production of antibody against human leukocytic pyrogen. J Clin Invest (1977) 1.84
An immobile subset of plasma membrane CD11b/CD18 (Mac-1) is involved in phagocytosis of targets recognized by multiple receptors. J Immunol (1989) 1.79
Requirements for the solubilization of immune aggregates by complement: assembly of a factor B-dependent C3-convertase on the immune complexes. J Exp Med (1977) 1.79
C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med (1984) 1.74
Studies of complement complex C5b,6 eluted from--EAC-6: reaction of C5b,6 with EAC4b,3b and evidence on the role of C2a and C3b in the activation of C5. J Immunol (1974) 1.73
Amino-terminal sequence of p36 and associated p10: identification of the site of tyrosine phosphorylation and homology with S-100. Proc Natl Acad Sci U S A (1985) 1.72
Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade. J Immunol (1986) 1.72
Increased ion permeability of planar lipid bilayer membranes after treatment with the C5b-9 cytolytic attack mechanism of complement. Proc Natl Acad Sci U S A (1976) 1.69
Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc Natl Acad Sci U S A (1987) 1.68
Third component of human complement: appearance of a sulfhydryl group following chemical or enzymatic inactivation. Biochemistry (1980) 1.67
Lack of binding of human C3, in its native state, to C3b receptors. J Immunol (1981) 1.57
On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b,6,7 complex into phospholipid bilayers of erythrocyte membranes. Proc Natl Acad Sci U S A (1975) 1.57
Characterization of the human complement (c3b) receptor with a fluid phase C3b dimer. J Immunol (1981) 1.55
Structural analysis of human complement protein H: homology with C4b binding protein, beta 2-glycoprotein I, and the Ba fragment of B2. J Immunol (1986) 1.53
Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol (2001) 1.52
Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry (1985) 1.49
Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis (1992) 1.49
Fifth component of human complement: purification from plasma and polypeptide chain structure. Biochemistry (1979) 1.49
Mechanism of inhibition of immunoglobulin G-mediated phagocytosis by monoclonal antibodies that recognize the Mac-1 antigen. J Clin Invest (1988) 1.45
Third component of human complement: structural analysis of the polypeptide chains of C3 and C3b. Biochemistry (1979) 1.44
Serum amyloid P component and C-reactive protein mediate phagocytosis through murine Fc gamma Rs. J Immunol (2001) 1.44
Spontaneous elaboration of transforming growth factor beta suppresses host defense against bacterial infection in autoimmune MRL/lpr mice. J Exp Med (1994) 1.43
On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes. J Immunol (1977) 1.41
Third component of human complement: structural requirements for its function. Biochemistry (1980) 1.38
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. J Immunol (1996) 1.37
Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc Natl Acad Sci U S A (1986) 1.37
Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics. Proc Natl Acad Sci U S A (1983) 1.35
An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(o)-mediated signal transduction. J Cell Biol (2001) 1.34
Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol (1986) 1.31
C3d receptors are expressed on human monocytes after in vitro cultivation. Proc Natl Acad Sci U S A (1983) 1.30
Nucleotide sequence of complementary DNA and derived amino acid sequence of murine complement protein C3. Philos Trans R Soc Lond B Biol Sci (1984) 1.29
Primary structure of bovine calpactin I heavy chain (p36), a major cellular substrate for retroviral protein-tyrosine kinases: homology with the human phospholipase A2 inhibitor lipocortin. Biochemistry (1986) 1.28
Inhibition of beta 2 integrin receptor and Syk kinase signaling in monocytes by the Src family kinase Fgr. Immunity (2001) 1.27
Orientation and dynamics of an antimicrobial peptide in the lipid bilayer by solid-state NMR spectroscopy. Biophys J (2001) 1.27
Entactin stimulates neutrophil adhesion and chemotaxis through interactions between its Arg-Gly-Asp (RGD) domain and the leukocyte response integrin. J Clin Invest (1992) 1.27
A quantitative analysis of C3 binding to O-antigen capsule, lipopolysaccharide, and outer membrane protein of E. coli 0111B4. J Immunol (1984) 1.26
Expression of the 50-kDa integrin-associated protein on myeloid cells and erythrocytes. J Immunol (1992) 1.25
Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+. J Immunol (1986) 1.25
The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob Agents Chemother (2001) 1.22
Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc Natl Acad Sci U S A (1988) 1.22
Biochemical characterization of a factor produced by trypomastigotes of Trypanosoma cruzi that accelerates the decay of complement C3 convertases. J Biol Chem (1988) 1.20
Third component of human complement: localization of the internal thiolester bond. Proc Natl Acad Sci U S A (1982) 1.20
Sequence determination of the thiolester site of the fourth component of human complement. Proc Natl Acad Sci U S A (1981) 1.19
The beta-Cys-gamma-Glu thiolester bond in human C3, C4, and alpha 2-macroglobulin. Springer Semin Immunopathol (1983) 1.18
Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. J Immunol (1990) 1.17
Binding of C3b proceeds by a transesterification reaction at the thiolester site. Nature (1982) 1.17
Fourth component of human complement: studies of an amine-sensitive site comprised of a thiol component. Biochemistry (1981) 1.17
Primary structure of the fifth component of murine complement. Biochemistry (1987) 1.16
A novel murine beta -defensin expressed in tongue, esophagus, and trachea. J Biol Chem (2000) 1.14
Congeners of SMAP29 kill ovine pathogens and induce ultrastructural damage in bacterial cells. Antimicrob Agents Chemother (2001) 1.14
Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci U S A (1985) 1.14
Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. J Immunol (1983) 1.12
Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother (2001) 1.10
Stimulation of human neutrophil Fc receptor-mediated phagocytosis by a low molecular weight cytokine. J Immunol (1986) 1.09
Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes. J Immunol (1983) 1.09
Immunologically mediated membrane damage: the mechanism of complement action and the similarity of lymphocyte-mediated cytoxicity. Immunochemistry (1978) 1.08
Intracellular demonstration of active TGFbeta1 in B cells and plasma cells of autoimmune mice. IgG-bound TGFbeta1 suppresses neutrophil function and host defense against Staphylococcus aureus infection. J Clin Invest (1996) 1.08
Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. J Cell Biol (1996) 1.08
Complement receptor expression by neoplastic and normal human cells. J Immunol (1983) 1.07
Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother (2001) 1.06
Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis (1986) 1.05
NH2-terminal structure and cleavage of guinea pig pro-C3, the precursor of the third complement component. J Biol Chem (1981) 1.05
The superfamily of C3b/C4b-binding proteins. Fed Proc (1987) 1.04
A new activity of complement component C3: cell-bound C3b potentiates lysis of erythrocytes by C5b,6 and terminal components. J Immunol (1976) 1.02
The interaction of C3b bound to pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. J Immunol (1983) 1.02
Structure of murine complement component C3. I. Nucleotide sequence of cloned complementary and genomic DNA coding for the beta chain. J Biol Chem (1984) 1.02
Biotinylation of human C3. Mol Immunol (1982) 1.02
Structure of murine complement component C3. II. Nucleotide sequence of cloned complementary DNA coding for the alpha chain. J Biol Chem (1984) 1.01
cDNA structure of murine C4b-binding protein, a regulatory component of the serum complement system. Biochemistry (1987) 1.01
ATPase center of bacteriophage lambda terminase involved in post-cleavage stages of DNA packaging: identification of ATP-interactive amino acids. J Mol Biol (2000) 0.99
A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose. J Immunol Methods (1989) 0.99
Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest (1985) 0.98
Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing. J Immunol (1987) 0.97
TnphoA-mediated disruption of K54 capsular polysaccharide genes in Escherichia coli confers serum sensitivity. Infect Immun (1993) 0.97
Chromosomal location of the genes encoding complement components C5 and factor H in the mouse. J Immunol (1986) 0.97
cDNA sequence and tissue distribution of the mRNA for bovine and murine p11, the S100-related light chain of the protein-tyrosine kinase substrate p36 (calpactin I). J Biol Chem (1987) 0.96
Isolation and sequence analysis of a cDNA clone encoding the fifth complement component. J Biol Chem (1985) 0.96
The fifth component of complement (C5) in the mouse. Analysis of the molecular basis for deficiency. J Exp Med (1987) 0.96